Efficacy and safety of short- and long-term treatment of itraconazole on chronic necrotizing pulmonary aspergillosis in multicenter study

被引:28
作者
Yoshida, Koichiro [1 ]
Kurashima, Atsuyuki [2 ]
Kamei, Katsuhiko [3 ]
Oritsu, Masaru [4 ]
Ando, Tsunehiro [5 ]
Yamamoto, Toshinori [6 ]
Niki, Yoshihito [1 ]
机构
[1] Showa Univ, Sch Med, Dept Internal Med, Div Clin Infect Dis,Shinagawa Ku, Tokyo 1428555, Japan
[2] Japan AntiTB Assoc, Fukujuji Hosp, Dept Resp Med, Tokyo, Japan
[3] Chiba Univ, Div Clin Res, Med Mycol Res Ctr, Chiba, Japan
[4] Japanese Red Cross Med Ctr, Dept Resp Med, Tokyo, Japan
[5] Japanese Red Cross Med Ctr, Dept Infect Dis, Tokyo, Japan
[6] Showa Univ, Sch Pharmaceut Sci, Dept Clin Pharm, Tokyo 1428555, Japan
关键词
Itraconazole; Chronic necrotizing pulmonary aspergillosis; Treatment; VORICONAZOLE; MICAFUNGIN; TRIAL;
D O I
10.1007/s10156-012-0414-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In the respiratory field, chronic pulmonary aspergillosis, such as chronic necrotizing pulmonary aspergillosis (CNPA) or aspergilloma, is important. We examined the efficacy and safety of short- and long-term itraconazole (ITCZ) administration, involving a switch from injection to an oral preparation, in patients with CNPA. In all hospitals participating in this study, the protocol was approved by the ethics review board. This study started after UMIN registration (UMIN000001727). Subjects enrolled in this study were patients who were clinically or definitively diagnosed with CNPA in the respiratory field, according to the diagnostic criteria of the Japanese "Guidelines for management of deep-seated mycosis 2007," in 16 hospitals that participated in this study between May 2008 and March 2011. Treatment was started with ITCZ injection. Subsequently, the agent was switched to an oral preparation. Efficacy was evaluated with major items (clinical symptoms, fever, imaging findings) and minor items (nutritional status, inflammatory markers). Twenty-nine patients were enrolled; safety was evaluated in 24 and efficacy in 23. Of the 23 patients, 10 (43.5 %) responded. With respect to the administration period, the response rates in 8 patients treated for a short period and 15 treated for a long period were 25.0 % and 53.3 %, respectively. Trough blood concentration of ITCZ reached a level at which ITCZ may be effective for aspergillosis at 3 days after the start of ITCZ injection therapy. After changing to high-dose capsules, its level was also maintained. Adverse events such as liver dysfunction and heart failure were observed in 9 of the 24 patients. Furthermore, 6 patients died. However, there was no relationship between these events and ITCZ. Step-down therapy from ITCZ injection to oral administration may be a useful treatment option in CNPA patients requiring long-term treatment.
引用
收藏
页码:378 / 385
页数:8
相关论文
共 13 条
  • [1] CHRONIC NECROTIZING PULMONARY ASPERGILLOSIS - A DISCRETE CLINICAL ENTITY
    BINDER, RE
    FALING, LJ
    PUGATCH, RD
    MAHASAEN, C
    SNIDER, GL
    [J]. MEDICINE, 1982, 61 (02) : 109 - 123
  • [2] Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients
    Camuset, Juliette
    Nunes, Hilario
    Dombret, Marie-Christine
    Bergeron, Anne
    Henno, Priscilla
    Philippe, Bruno
    Dauriat, Gaelle
    Mangiapan, Gilles
    Rabbat, Antoine
    Cadranel, Jacques
    [J]. CHEST, 2007, 131 (05) : 1435 - 1441
  • [3] Deep-Seated Mycosis Guidelines Editorial Committee, 2007, GUID MAN DEEP SEAT M
  • [4] NIAID MYCOSES STUDY-GROUP MULTICENTER TRIAL OF ORAL ITRACONAZOLE THERAPY FOR INVASIVE ASPERGILLOSIS
    DENNING, DW
    LEE, JY
    HOSTETLER, JS
    PAPPAS, P
    KAUFFMAN, CA
    DEWSNUP, DH
    GALGIANI, JN
    GRAYBILL, JR
    SUGAR, AM
    CATANZARO, A
    GALLIS, H
    PERFECT, JR
    DOCKERY, B
    DISMUKES, WE
    STEVENS, DA
    [J]. AMERICAN JOURNAL OF MEDICINE, 1994, 97 (02) : 135 - 144
  • [5] Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-β-cyclodextrin oral solution or coated-pellet capsules
    Glasmacher, A
    Hahn, C
    Molitor, E
    Marklein, G
    Sauerbruch, T
    Schmidt-Wolf, IGH
    [J]. MYCOSES, 1999, 42 (11-12) : 591 - 600
  • [6] Hagiwara E, 2008, J JPN RESP SOC, V46, P864
  • [7] Kohno S, 2006, JPN J CHEMOTHER S1, V54, P32
  • [8] KOHNO S, 2010, JPN J CHEMOTHER, V58, P128
  • [9] Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: A multicenter trial in Japan
    Kohno, Shigeru
    Izumikawa, Koichi
    Ogawa, Kenji
    Kurashima, Atsuyuki
    Okimoto, Niro
    Amitani, Ryoichi
    Kakeya, Hiroshi
    Niki, Yoshihito
    Miyazaki, Yoshitsugu
    [J]. JOURNAL OF INFECTION, 2010, 61 (05) : 410 - 418
  • [10] Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases
    Nam, Hae-Seong
    Jeon, Kyeongman
    Um, Sang-Won
    Suh, Gee Young
    Chung, Man Pyo
    Kim, Hojoong
    Kwon, O. Jung
    Koh, Won-Jung
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 (06) : E479 - E482